Symptoms of common mental disorder and cognitive associations with seropositivity among a cohort of people coming for testing for HIV/AIDS in Goa, India: a cross-sectional survey. by Mayston, Rosie et al.
Mayston, R; Patel, V; Abas, M; Korgaonkar, P; Paranjape, R; Ro-
drigues, S; Prince, M (2013) Symptoms of common mental disorder
and cognitive associations with seropositivity among a cohort of peo-
ple coming for testing for HIV/AIDS in Goa, India: a cross-sectional
survey. Bmc Public Health, 13. ISSN 1471-2458 DOI: 10.1186/1471-
2458-13-204
Downloaded from: http://researchonline.lshtm.ac.uk/856595/
DOI: 10.1186/1471-2458-13-204
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE Open Access
Symptoms of common mental disorder and
cognitive associations with seropositivity among
a cohort of people coming for testing for
HIV/AIDS in Goa, India: a cross-sectional survey
Rosie Mayston1*, Vikram Patel2,3, Melanie Abas1, Priya Korgaonkar3, Ramesh Paranjape4, Savio Rodrigues5
and Martin Prince1
Abstract
Background: The majority of research on HIV/AIDS and mental health has been carried out among clinical
populations: the time of onset of comorbid depression and the mechanisms for this are therefore unclear. Although
there is evidence to suggest that asymptomatic people living with HIV/AIDS exhibit some cognitive deficits, the
prevalence of poor cognitive functioning among people in low income settings at an early, pre-clinical stage has
not yet been investigated.
Methods: We used a cross-sectional survey design to test the hypotheses that symptoms of Common Mental
Disorder (CMD) and low scores on cognitive tests would be associated with seropositivity among participants
coming for testing for HIV/AIDS. Participants were recruited at the time of coming for testing for HIV/AIDS;
voluntary informed consent was sought for participation in research interviews and data linkage with HIV test
results. Baseline questionnaires including sociodemographic variables and measures of mental health (PHQ-9,
GAD-7, panic disorder questions, AUDIT and delayed word list learning and recall and animal naming test of verbal
fluency) were administered by trained interviews. HIV status data was extracted from clinical records.
Results: CMD and scoring below the educational norm on the test of verbal fluency were associated with testing
positive for HIV/AIDS in bivariate analysis (OR = 2.26, 1.31-3.93; OR = 1.77, 1.26-2.48, respectively). After controlling for
the effects of confounders, the association between CMD and seropositivity was no longer statistically significant
(AOR = 1.56, 0.86-2.85). After adjusting for the effects of confounders, the association between low scores on the
test of verbal fluency and seropositivity was retained (AOR = 1.77, 1.27-2.48).
Conclusions: Our findings provide tentative evidence to suggest that low cognitive test scores (and possibly
depressive symptoms) may be associated with HIV status among people who have yet to receive their HIV test
results. Impaired cognitive functioning and depression-like symptoms may be the result of the same underlying
neurological damage. CMD and cognitive impairment may overlap to a greater extent than previously assumed. If
replicated, this may have implications for the way in which we measure and treat CMD and cognitive functioning
among people living with HIV/AIDS.
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Background
High levels of common mental disorder have been iden-
tified among people living with HIV/AIDS in communi-
ties around the world [1-5], including in India [6]. There
is evidence from low and middle income and high in-
come settings that Common Mental Disorders (CMD)
such as depression have an adverse impact upon adher-
ence [7-9], as well as additional negative effects upon
HIV-related clinical outcomes such as disease progres-
sion and survival, that are independent of the effects
of common mental disorder upon adherence [10,11].
Neurocognitive impairment usually thought to be due to
HIV-related damage to the frontostriatal region of the
brain is generally found to occur among 20–37 percent
of people living with HIV/AIDS [12] and is associa-
ted with HIV-associated dementia, disease severity [13],
mortality [14], adherence to antiretroviral therapy [15]
and employment [16]. The precise mechanisms for the
high prevalence of comorbid neurocognitive impairment
with HIV/AIDS are not well understood but recent stud-
ies have found reduced subcortical volumes and metab-
olite abnormalities among HIV-positive participants on
cART [17].
Although diagnosis and life events related to diagnosis
and disclosure undoubtedly contribute to the poor men-
tal health of people living with HIV/AIDS [18,19], there
is evidence to suggest that the presence of HIV in the
brain may also play a role in producing depression-like
symptoms [20]. The majority of research on HIV/AIDS
and mental health has been carried out among clinical
populations: the time of onset of comorbid depression
and the mechanisms for this are therefore unclear. Al-
though there is evidence to suggest that asymptomatic
people living with HIV/AIDS exhibit some cognitive def-
icits [21], the prevalence of poor cognitive functioning
among people in low income settings at an early, pre-
clinical stage has not yet been investigated.
The few researchers who have measured depression
among people coming for testing in low income settings
have generally found a high prevalence (45 percent in an
Indian sample [6]; 41 percent among pregnant women
in South Africa [22]). Depression was not found to be
associated with testing positive for HIV/AIDS in either
these samples.
The limited data available on HIV-associated cognitive
impairment in low income settings generally indicates
lower cognitive functioning among seropositive partici-
pants as compared to seronegative controls [12]. Preva-
lence estimates of impairment vary- a multicentre WHO
survey found impairment among symptomatic individuals
of between 13 and 19 percent [21], whereas recent studies
carried out in India, China, Uganda and Botswana com-
paring HIV-positive with HIV-negative controls reported
prevalence of between 31 and 56 percent [12,23].
The aim of the Umeed study was to investigate the re-
lationship between CMD symptoms cognitive function-
ing and HIV/AIDS among a cohort of people attending
a public clinic for HIV-testing. At the time of interview,
study participants were not aware of their HIV status.
Given the evidence to support a biological pathway be-
tween HIV infection and common mental disorder and
cognitive impairment, we hypothesised that CMD symp-
toms and cognitive impairment would predict testing
positive for HIV/AIDS among a sample that were not
yet aware of the outcome of their test.
Methods
Design
Analysis of cross-sectional data from the “Umeed” co-
hort is presented here. Participants were recruited at the
time of attending for pre-test counselling and testing
for HIV/AIDS at Goa Medical College. Structured in-
terviews including questions about demographics, HIV-
related factors, as well as measures of CMD symptoms
and alcohol and substance misuse were carried out in
the clinic setting at the time of attendance for pre-test
counselling and testing. Participants were then followed
up via routine records in order to obtain HIV status and
attendance of post-test counselling data.
In order to test the hypothesis that CMD symptoms
and/or cognitive impairment would predict seropositiv-
ity among those without knowledge of their HIV status,
study participants who reported having previously been
tested for HIV/AIDS and who had received a seropositive
result were excluded from analyses (n = 57) presented in
Tables 1, 2, 3, 4 and 5.
Setting
Goa, the smallest Indian state by area, is situated on the
west coast between Maharashtra and Karnataka and has
a population of 1.34 millions (Government of Goa, 2010).
For HIV/AIDS surveillance, Goa is divided into two dis-
tricts: the north is described as one of India’s high preva-
lence districts, with more than one percent prevalence
among women at antenatal care. The south is medium
prevalence, with more than five percent prevalence found
among those attending STI clinics (high risk group)
(UNAIDS, 2008).
Recruitment and measures
Participants were recruited at the time of attending the
largest public Integrated Counselling & Testing Centre
(ICTC) for pre-test counselling and testing. In 2008,
20.8 percent of attendees were “walk-in”, self-referrals,
whilst the majority of people tested attended upon the
recommendation of a Doctor (Goa State AIDS Control
Society, 2012). Doctors refer participants for testing for
a variety of reasons, including: unexplained or suspected
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Table 1 Characteristics of the sample
Prevalence n (%)
Total 1874
Male 880 (47.0)
Female 994 (53.0)
Age
18–25 441 (23.5)
26–30 357 (19.1)
31–34 292 (15.6)
35–40 282 (15.0)
41–45 162 (8.6)
46–50 150 (18.0)
51+ 190 (10.1)
Language
Hindi 628 (33.5)
Konkani 1178 (62.9)
English 68 (3.6)
Religion
Hindu 1370 (73.1)
Christian 295 (15.7)
Muslim 206 (11.0)
Other 2 (0.1)
State of origin
Goa 1053 (56.1)
Other than Goa 821 (43.8)
Marital status
Married/co-habiting 1315 (70.2)
Widowed 13 (0.7)
Separated/divorced 127 (6.8)
Never married 419 (22.3)
Education
None 335 (17.9)
Primary school 471 (25.1)
Secondary school 915 (48.8)
Further education 153 (8.2)
CMD symptoms 100 (5.3)
Symptoms of major depression 76 (4.05)
Symptoms of generalised anxiety 20 (1.1)
Symptoms of panic 30 (1.6)
Symptoms of major depression + scored
more than 5 on GAD-7
51 (2.7)
Symptoms of generalised anxiety + scored
more than 5 on PHQ-9
19 (1.0)
Symptoms of panic + scored more than
5 on PHQ-9
27 (1.4)
Abstinent/occasional alcohol use 1636 (87.2)
Harmful alcohol use 240 (12.8)
Table 1 Characteristics of the sample (Continued)
Cognitive functioning
Delayed recall- Scored below
educational
norm
427 (22.8)
Verbal fluency- Scored below
educational norm
480 (25.6)
Experienced domestic violence in
the last 12m
Yes 116 (6.2)
Perpetrated domestic violence in
the last 12m
Yes 81 (4.3)
Frequency of social outings, ie.
visiting a friend/relative
Often (at least 1/week) 94 (5.0)
Sometimes (at least 1/month) 157 (8.4)
Rarely (less than once 1/month) 922 (49.2)
Never 701 (37.4)
Frequency of having friends/relatives
coming to visit
Often (at least 1/week) 112 (6.0)
Sometimes (at least 1/month) 470 (25.0)
Rarely (less than once 1/month) 815 (43.5)
Never 477 (25.5)
Ever experienced hunger due to lack
of money
Yes 347 (18.5)
Accompanied to the ICTC
No 695 (37.01)
Plan to disclose HIV/AIDS test results
Yes 1489 (79.5)
No 340 (18.1)
Don’t know 45 (2.4)
Knowledge of HIV prevention
Thorough 1433 (76.5)
Partial/poor 441 (23.5)
Knowledge of HIV transmission
Thorough 576 (30.7)
Partial 698 (37.3)
Poor 600 (32.0)
Internalised stigma v. people living
with HIV/AIDS
None 675 (36.0)
Moderate 607 (32.4)
Strong 592 (31.6)
Anticipated stigma if tested positive
for HIV/AIDS
None 602 (32.1)
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HIV-related symptoms, pre-operative tests. Self-referrals
include those who believe themselves to be at high-risk
as well as those undergoing pre-marital tests or testing
before going to work abroad. Potential participants were
informed about the study by trained research assistants;
consent for participation and data linkage with test re-
sults was sought. The study was approved by local and
international research ethics committees (Sangath and
KCL).
Questionnaires, administered by research assistants
using palmtop computers were carried out at the time of
participants coming for testing. In order to maximise
privacy and quietness, interviews were carried out in
purpose-built temporary cabins situated in the clinic re-
ception area. People attending the ICTC for pre-test
counselling and testing for HIV/AIDS were eligible to
participate if they met the following inclusion criteria:
demonstration of capacity- understanding the aims of
the study and demands of participation and able to give
informed consent; fluent in one of three local languages
(Konkani, Hindi & English); aged more than eighteen
years of age. Questions relating to demographics, HIV-
related behaviours, beliefs and knowledge (transmission
and prevention knowledge, disclosure plans, sexual be-
haviour, knowledge and symptoms of sexually transmit-
ted infections) and measures of mental health were
included in baseline interviews.
In order to access free-of-charge antiretroviral treat-
ment services, it is necessary to present a test certificate
from a state-run testing centre. Therefore, testing in the
private sector, followed by re-testing at a public testing
centre is relatively common. Participants were therefore
asked if they had previously undertaken a HIV-test; those
who had received test results were asked to disclose the
result to interviewers.
CMD and alcohol use
A modified version of the Patient Health Questionnaire,
the brief PHQ-9, in combination with the 7-item Gener-
alised Anxiety Disorder scale (GAD-7), plus the panic
disorder module [24] were included in the baseline ques-
tionnaire to measure symptoms of depression, anxiety
and panic. In a study comparing the sensitivity and spe-
cificity of five screeners for CMD in primary care which
carried out in Goa, the PHQ was one of five instruments
to achieve an AUC from ROC analysis of at least 0.80
(PHQ AUC = 0.84) [25]. In Umeed, as recommended by
Spitzer et al. [24], a cut-off of 10 was used as an indica-
tor for symptoms of major depression. A cut-off of 10
was used to indicate symptoms of severe generalised
anxiety [26]. Participants reporting “yes” to each of the
first four questions relating to anxiety attacks were indi-
cated as panic disorder cases in the Umeed study. At the
time of conducting the study, there were no measures of
anxiety symptoms that had been validated in a local
HIV-affected population. Therefore, we decided to use
brief measures that showed good validity in primary care
populations elsewhere. Given the evidence to support
distinctive diagnostic categories of depression and anx-
iety [27-29], participants identified as having symptoms
of major depression and/or generalised anxiety disorder
and/or panic disorder were categorised as having com-
mon mental disorder during analysis. “CMD symptoms”
does not refer to a clinical diagnosis but to the result
of the screening procedure used in this epidemiolo-
gical study.
Table 1 Characteristics of the sample (Continued)
Moderate 511 (27.3)
Strong 761 (40.6)
Ever injected a non-prescription drug
Yes 2 (0.1)
Ever had sex
No 293 15.20
Male who had sex with a man during
the last year
Yes 14 0.75
Ever had sex with someone other than
your regular partner in last 12m
Yes 225 (12.0)
Ever received cash, gifts or favours in
exchange for sex
Yes 33 (1.8)
Ever had sex with someone who was
a commercial sex-worker
Yes 90 (4.8)
Has experienced pain/burning with
urination
Yes 364 (19.4)
Genital sores
Yes 119 (6.4)
Genital warts
Yes 61 (3.3)
Genital discharge
Yes 327 (17.5)
Believes likely to test positive for HIV/AIDS
Yes 35 (1.9)
Don’t know 478 (25.5)
Have a child or partner who is HIV-
positive
Don’t know 106 (5.7)
Yes 106 (5.7)
HIV status
Positive 164 (8.8)
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Table 2 Bivariate associations of with testing positive for HIV/AIDS
HIV-positive n (%) OR (95% CI) p
Total 164 (8.75)
Demographics
Male 78 (8.86) 1.00 0.97
Female 86 (8.65) 0.97 (0.71–1.34)
Age
18–25 17 (3.85) 1.09 (1.00–1.18) 0.04
26–30 35 (9.80)
31–34 32 (10.96)
35–40 33 (11.70)
41–45 18 (11.11)
46–50 17 (11.33)
51+ 12 (6.32)
Language
Hindi 72 (11.46) 1.00
Konkani 91 (7.72) 0.65 (0.47–0.90) 0.01
English 1 (1.47) 0.12 (.0.02–0.85) 0.01
State of origin
Goa 69 (6.55) 1.00 <0.01
Other than Goa 95 (11.57) 1.87 (1.35–2.58)
Marital status
Married/co-habiting 119 (9.05) 1.00
Widowed 23 (18.11) 2.22 (1.36–3.63) <0.01
Separated/divorced 3 (23.08) 3.01 (0.82–11.13) 0.08
Never married 19 (4.53) 0.48 (0.29–0.79) <0.01
Education
None 46 (13.73) 0.70 (0.58–0.84) <0.01
Primary school 44 (9.34)
Secondary school 66 (7.21)
Further education 8 (5.23)
Mental Health and Social Support
No/mild CMD symptoms 147 (8.29) 1.00 <0.01
Moderate/severe CMD symptoms 17 (17.00) 2.27 (1.31–3.93)
Abstinent/occasional alcohol use 137 (8.38) 1.00 0.14
Harmful alcohol use 27 (11.25) 1.39 (0.89–2.14)
Cognitive functioning 2.47 (1.40–4.34)
Delayed recall- Scored above educational norm 117 (8.09) 1.00
Delayed recall- Scored below educational norm 47 (11.01) 1.41 (0.98–2.01) 0.06
Verbal fluency- Scored above educational norm 104 (7.46) 1.00
Verbal fluency- Scored below educational norm 60 (12.50) 1.77 (1.26–2.48) <0.01
Frequency of social outings, ie. visiting a friend/relative
Often (at least 1/week) 3 (3.19) 1.53 (1.25–1.88) <0.01
Sometimes (at least 1/month) 14 (8.92)
Rarely (less than once 1/month) 56 (6.07)
Never 91 (12.98)
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Table 2 Bivariate associations of with testing positive for HIV/AIDS (Continued)
Frequency of having friends/relatives coming to visit
Often (at least 1/week) 8 (7.14) 1.38 (1.14–1.66) <0.01
Sometimes (at least 1/month) 34 (7.23)
Rarely (less than once 1/month) 56 (6.87)
Never 66 (13.84)
Ever experienced hunger due to lack of money
No 112 (7.33) 1.00 <0.01
Yes 52 (14.99) 2.23 (1.56–3.17)
Plan to disclose HIV/AIDS test results
Yes 116 (7.79) 1.00
No 44 (12.94) 1.76 (1.22–2.55) <0.01
Don’t know 4 (8.89) 1.15 (0.41–3.28) 0.79
Ever had sex
No 12 (4.10) 1.00 <0.01
Yes 152 (9.61) 2.49 (1.36–4.55) <0.01
Ever had sex with someone other than your regular
partner in last 12m
No 136 (8.25) 1.00 0.04
Yes 28 (12.44) 1.58 (1.02–2.44)
Ever had sex in exchange for money, favours or gifts
No 157 (8.53) 1.00 0.01
Yes 7 (21.21) 2.89 (1.23–6.77)
Ever had genital warts
No 153 (8.44) 1.00 0.01
Yes 11 (18.03) 2.39 (1.22–4.69)
Believes likely to test positive for HIV/AIDS
No 72 (5.29) 1.00 <0.01
Don’t know 78 (16.32) 3.49 (2.47–4.93)
Yes 14 (40.00) 11.94 (5.72–24.91)
Have a child or partner who is HIV-positive
No 103 (6.20) 1.00
Don’t know 18 (16.82) 3.06 (1.77–5.29) <0.01
Yes 43 (40.57) 10.32 (6.54–16.30) <0.01
Table 3 Multivariate models adjusting for confounders of association between CMD symptoms and testing
seropositive
Model Description Adjusted OR (95% confidence interval) P-value
1 CMD symptoms 2.27 (1.31-3.92) <0.01
2 Model 1 + education 2.04 (1.18-3.56) 0.01
3 Model 2 + experience of hunger due to lack of money 1.84 (1.05-3.22) 0.03
4 Model 3 + disclosure plans 1.73 (0.99-3.05) 0.06
5 Model 4 + genital warts 1.65 (0.93-2.92) 0.09
6 Model 5 + perceived likelihood of testing positive 1.50 (0.83-2.73) 0.18
7 Model 6 + cognitive functioning: verbal fluency 1.56 (0.86-2.85) 0.14
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The AUDIT is a 10 item questionnaire designed to
measure medium (cut-off of eight) and high levels (cut-
off of 16) of alcohol problems (WHO 2001). The instru-
ment has been widely used in India ie. [30,31] and in
studies conducted in Goa [32,33]. A recent validity study
conducted in Goa demonstrated good sensitivity and
specificity for the AUDIT, with an area under the curve
of more than 0.80 [34]. For analysis, participants were
categorised as hazardous drinkers if they scored above
eight.
Cognitive functioning
Two measures of cognitive functioning were included in
the Umeed questionnaire: word list learning (assessing
memory) and animal naming (measuring verbal fluency,
an aspect of executive functioning, known to be a com-
mon deficit in people living with HIV/AIDS- [35]). The
terms “low cognitive functioning” and “cognitive deficits”
apply to the two domains tested only. Due to the broa-
der aims of Umeed (investigating impact of psycholo-
gical factors upon access to care) and the practicalities
of measuring cognition in a busy clinic setting, we used
brief, simple screeners to measure domains that may be
impacted by HIV and that were most likely to be impli-
cated in determining access to services.
For the word list learning test, interviewers read out a
ten word list (adapted for use in India- [36]) three times.
Participants were then asked to recite the list of words
after each reading and finally requested to recall words
after another section of the questionnaire had been com-
pleted. The final total recalled was recorded. For the ani-
mal naming test, participants were asked to tell the
interviewer as many different types of animals as they
could recall during one minute.
These tests originate from the Consortium to Establish
a Registry of Alzheimer’s Disease (CERAD) test battery
and have been validated among an older population in
Goa as part of the validation of a cross-cultural diagnos-
tic instrument for dementia [37]. Normative data was
available, in the form of education-specific norms de-
rived from the 10/66 study data for the youngest of the
older age-group (60–64 years). Education-specific cut-
points for possible cognitive impairment at 1.5 standard
deviations below the norms were used in the Umeed
study as indicators of low cognitive function.
Outcome measures
Outcome data was collected from routine clinical re-
cords maintained by ICTC staff by an Umeed team
member who was not involved in baseline data col-
lection. HIV status and date of attendance of post-test
counselling (if attended) was extracted from ICTC re-
cords. Study participants records were identified using
the unique identifier assigned to participants by counsel-
lors at pre-test counselling.
Table 4 Multivariate models adjusting for confounders of association between low cognitive functioning score (test 1)
and testing seropositive
Model Description Adjusted OR (95% confidence interval) P-value
1 Cognitive functioning: test 1 1.41 (0.98-2.01) 0.06
2 Model 1 + age 1.37 (0.96-1.97) 0.08
3 Model 2 + education 1.33 (0.93-1.90) 0.12
4 Model 3 + experience of hunger due to lack of money 1.26 (0.88-1.82) 0.21
5 Model 4 + perceived likelihood of testing positive 1.17 (0.80-1.70) 0.42
6 Model 5 + cognitive functioning test: verbal fluency 1.02 (0.68-1.51) 0.94
Table 5 Multivariate models adjusting for confounders of association between low cognitive functioning score : verbal
fluency and testing seropositive
Model Description Adjusted OR (95% confidence interval) P-value
1 Cognitive functioning: verbal fluency 1.77 (1.27-2.48) <0.01
2 Model 1 + age 1.76 (1.26-2.47) <0.01
3 Model 2 + education 1.73 (1.23-2.42) <0.02
4 Model 3 + language 1.65 (1.18-2.33) <0.01
5 Model 4 + marital status 1.71 (1.21-2.40) <0.01
6 Model 5 + CMD symptoms 1.74 (1.24-2.46) <0.01
7 Model 6 + has child/partner who is living with HIV/AIDS 1.63 (1.13-2.34) 0.01
8 Model 7 + perceived likelihood of testing positive 1.61 (1.12-2.33) 0.01
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Analysis
Bivariate analysis was carried out. chi-squared tests were
used to test differences between distribution of HIV sta-
tus outcome between categories of a) hypothesised expo-
sures of interest (common mental disorder, cognitive
functioning) and b) potential demographic, HIV-related
and psychosocial confounders. Mantel Haenszel odds ra-
tios comparing odds of testing positive for HIV among
exposure categories found to be associated with sero-
positivity in chi-squared analyses are presented in Table 1
with 95 percent confidence intervals.
Where there was evidence from bivariate analysis of
an association between exposures of interest and testing
positive for HIV/AIDS, multivariate analysis was carried
out to further test the hypotheses that CMD symptoms
and cognitive impairment would predict seropositivity.
Exposures of interest were entered singly into logistic re-
gression models. Potential confounders were then entered
one-by-one. Criteria for inclusion in final models were:
a) variables considered a priori confounders (for example,
association of age with cognitive functioning); or b) vari-
ables selected using a “change in estimate” method ie.
those that resulted in a significant change in the effect of
exposure of interest upon outcome (more than 10 percent
change in odds ratio).
Results
Characteristics of the sample
As described in Table 1, 8.8 percent of the sample tested
seropositive. The majority of the sample were female
(53.0 percent); the mean age of participants was 35 years.
Almost three quarters were Hindu (73.0 percent) and the
majority were born in Goa (56.1 percent). Most were
married (70.2 percent); 25.1 percent had attended up
to primary school whilst 17.9 percent had received no
education at all. 18.5 percent reported ever having ex-
perienced hunger due to lack of money.
The prevalence of CMD symptoms among this sample
of people of people coming for testing for HIV/AIDS
was 5.3 percent. 12.8 percent of participants reported
hazardous alcohol use (26.4 percent among men- not
presented). Around a quarter of the sample scored below
the educational norm on two cognitive tests of delayed
recall (22.8 percent) and verbal fluency (25.6 percent).
Analysis of associations with testing positive for HIV/AIDS
As described in Table 2, in bivariate analysis, CMD
symptoms and scoring below the educational norm on
verbal fluency test were associated with testing positive
(OR = 2.27, 1.31-3.93; OR = 1.77, 1.26-2.48, respectively).
There was a trend towards an association between scor-
ing below educational norm on the test of delayed recall
and seropositivity (OR = 1.41, 0.98-2.01). Hazardous al-
cohol use was not associated with seropositivity.
All variables found to be associated with testing positive
are presented in Table 2. Sociodemographic variables as-
sociated with testing positive included: age (OR = 1.09,
1.00-1.18), language (those speaking Konkani or English
were less likely to test positive than those speaking Hindi:
OR = 0.65, 0.47-0.90; OR = 0.12, 0.02-0.85, respectively),
being born outside of Goa (OR = 1.87, 1.35-2.58), being
widowed (OR = 2.22, 1.36-3.63), having experienced hun-
ger due to lack of money (OR = 2.23, 1.56-3.63). Visiting
relatives or friends (or receiving visits) less than once a
week was associated with seropositivity (OR = 1.53, 1.25–
1.88, OR = 1.38, 1.14-1.66, respectively). Education was
associated with a reduced likelihood of testing positive
(OR = 0.70, 0.58-0.84).
A number of HIV-related variables were also associ-
ated with seropositivity, including: planning not to dis-
close test results (OR = 1.76, 1.22-2.55), having sex with
someone other than a regular partner (OR = 1.58, 1.02-
2.44), having sex in exchange for cash, gifts or favours
(OR = 2.89, 1.23-6.77), believing it is likely that the test
result will be positive (OR = 11.94, 5.72-24.91), having a
child/partner who is living with HIV/AIDS (OR = 10.32,
6.54-16.30).
Variables tested but not found to be associated with
HIV status (results not presented in table) included:
internalised (p = 0.16) and anticipated stigma (p = 0.40),
knowledge of HIV prevention (0.38) and transmission
(p = 0.18).
Table 3 shows that, after controlling for the effects of
confounders (education, experience of hunger due to
lack of money, disclosure plans, genital warts, perceived
likelihood of testing positive and verbal fluency), the
association between CMD symptoms and seropositivity
is no longer statistically significant (AOR = 1.56, 0..86-
2.85). As presented in Table 4, the trend towards an as-
sociation between delayed recall and testing positive is
eliminated by the addition of confounding variables (age,
education, experience of hunger due to lack of money,
perceived likelihood of testing positive, verbal fluency) to
the model (AOR = 1.02, 0.68-1.51).
However, as can be seen in Table 5, although the ad-
dition of potential confounders of the association bet-
ween verbal fluency and seropositivity (age, education,
language, marital status, CMD symptoms, having a
child/partner who is seropositive, perceived likelihood of
testing positive) reduced the effect size, in the final mo-
del, verbal fluency remains significantly associated with
testing positive for HIV/AIDS (AOR = 1.77, 1.27-2.48).
Discussion
The Umeed cohort is the largest study to describe the
mental health of people coming for testing for HIV/
AIDS in a low income setting. The inclusion of seroposi-
tive and seronegative attendees of HIV testing provided
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us with a unique opportunity to test hypotheses about
mental health and HIV status in the absence of the im-
pact of diagnosis and consequent experiences of living
with HIV/AIDS upon participant’s mental health. We
hypothesised that CMD symptoms and cognitive im-
pairment would be associated with testing positive. Our
findings were inconclusive. Although CMD symptoms
was strongly associated with testing positive in bivariate
analyses, after adjustment for confounders, the effect size
of this association was reduced and no longer statistically
significant. We found some evidence to support the hy-
pothesised association between low cognitive functioning
and seropositivity. Although there was only a bivariate
trend towards an association between delayed recall and
seropositivity, scoring below education-adjusted norms
on the test of verbal fluency (animal naming) was as-
sociated with testing positive for HIV/AIDS (AOR = 1.77,
1.27-2.48).
Almost all of the large body of research about HIV/
AIDS and CMD in low and middle income settings has
been carried out among single groups, with a HIV-
positive diagnosis, without comparison with seronegative
controls (for example, [5,38,39]). A few studies have
compared prevalence of depression between seropositive
and seronegative groups (ie. [4,40]). In one of the few
studies similar in design to Umeed (a sample of test-
seekers in Pune where 45.5 percent subsequently re-
ceived a positive diagnosis), univariate analyses revealed
no evidence of an association between common mental
disorder and seropositivity [6]. In the Umeed sample,
bivariate analysis revealed a strong association between
CMD and testing HIV-positive (OR = 2.27, 1.31-3.92).
However, after the gradual introduction of covariates
into the model, the effect size was reduced and no lon-
ger statistically significant (AOR = 1.56, 0.86-2.85).
Although the multivariate analysis presented in Table 3
demonstrates that the association between CMD symp-
toms and seropositivity was partially confounded by so-
ciodemographic and HIV-related covariates, we should
be cautious before interpreting these findings as a dem-
onstration that there was no true association between
CMD symptoms and seropositivity. As indicated by the
relatively wide confidence intervals presented in Table 3,
the low prevalence of both CMD and seropositivity
among Umeed participants (and particularly in the sub-
sample used for this analysis) resulted in reduced power
to detect an association, therefore we cannot rule out
the existence of a true association between CMD and
seropositivity.
As described, the prevalence of CMD symptoms iden-
tified among the Umeed sample was much lower than
that reported among the two other samples of people
coming for testing in low and middle income settings
described in the literature. The relatively low prevalence
of HIV/AIDS measured in Umeed as compared to these
other samples (45.5% in India; 40.9% among pregnant
women in South Africa) may help to explain the differ-
ence in prevalence of CMD symptoms. The Umeed sam-
ple is heterogeneous and includes participants at high
and low-risk of testing positive. Therefore, it is plausible
that the overall prevalence in the Umeed sample may be
more similar to that found in the local community [41],
rather than that identified in primary care [42]. Without
further research among people coming for testing in
similar settings, it is difficult to contextualise our find-
ings further. Of course, the possibility that our mode of
measurement of CMD symptoms may have contributed
to the low reported prevalence of CMD symptoms can-
not be ruled out. Although the PHQ-9 is commonly
used in Western settings, the lack of validation of cut-
points for use among HIV-affected populations in low
income settings may have had an impact upon the low
prevalence of common mental disorder identified in the
Umeed cohort. As described, all interviews were carried
out in temporary, private cabins. All participants were
given detailed information about CMD symptoms and
the aims and objectives of the study; the PHQ has been
found to be valid among a Goan sample of people at-
tending primary care. However, the possibility remains
that using the PHQ-9 immediately prior to testing in
the busy clinic setting may have inhibited participants
willingness to disclose potentially sensitive information
about symptoms of anxiety and depression. Our ana-
lysis demonstrated a high degree of co-morbidity of
symptoms of anxiety and depression within our sam-
ple (of those scoring >10 on the GAD-7, 75 percent
scored >10 on the PHQ-9; of those scoring >10 on
the PHQ-9, 20 percent scored >10 on the GAD-7 and
47.4 percent scored between 5 and 10 on the GAD-7),
thus supporting the dichotomous “symptoms of CMD”
variable used in our analysis.
Given that HIV/AIDS is associated with morbidity,
stigma and discrimination [43,44], poverty [45] and mor-
tality [46,47], it is reasonable to expect that living with
the disease contributes greatly to the prevalence of
CMD among people with HIV/AIDS. However, there is
evidence from neurological research to suggest that the
inflammatory response that contributes to the neuronal
loss that causes HIV-associated cognitive impairment
may also trigger cytokine-induced depression [20]. Re-
cent research suggests that even in the absence of other
symptoms of depression and cognitive impairment, HIV-
related damage to white matter may be associated with
symptoms of apathy (“reduced self-initiated cognitive,
emotional and behavioural activity”) [48]. In addition to
social and environmental risk factors associated with their
disease status, people living with HIV/AIDS (and other
chronic conditions) may have a biological vulnerability to
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the development of depressive symptoms [46]. Although
evidence suggesting that CMD may be associated with
risky behaviour [47,49] means that a reverse relationship
(pre-existing depression promoting sexual risk-taking and
acquisition of HIV) cannot be ruled out, presence of geni-
tal warts and perception of HIV-risk were the only sexual
risk-related variables, that confounded the association be-
tween CMD symptoms and seropositivity- therefore this
pathway seems unlikely.
The Umeed finding that low scores on the test of ver-
bal fluency were associated with seropositivity corre-
sponds with the results of a recent meta-analysis that
revealed a statistically significant deficit in mean scores
on tests of verbal fluency among people living with HIV/
AIDS, as compared to HIV-negative controls (−0.31,
−0.44 to −0.18) [50]. In the only study to compare verbal
fluency between seropositive individuals and seronega-
tive controls in India, although HIV-positive individuals
differed in other language-related domains (phonemic
fluency, verbal working memory and verbal learning and
memory); differences in animal naming fluency were not
statistically significant [51]. Similarly, statistically signifi-
cant deficits in verbal learning and memory were identi-
fied between seropositive individuals and seronegative
controls in a previous south Indian study [52].
Neurological evidence supports the presence of cogni-
tive deficits early in the course of the disease [12]. Both
cognitive domains measured in Umeed (category fluency
and verbal learning and memory) are consistent with dif-
fuse or frontostriatal pathology, both of which may be
characteristic of the effects of HIV-1 on the brain [50].
There is now a growing body of evidence on the cog-
nitive profile of people living with HIV/AIDS in low
income settings, including India [52]. Whereas small
studies with detailed neuropsychological assessments tend
to have stringent exclusion criteria which may limit the
generalisability of findings, in Umeed, exclusion criteria
were limited, meaning that our sample was likely to be
more representative of the base population. The aim of
Umeed was to measure cognitive functioning in the se-
lected domains most likely to have an impact upon linkage
to care and adherence and to examine whether these were
associated with testing positive. The animal naming test of
category fluency and the word list learning test of verbal
learning and memory were selected as appropriate mea-
sures that would be relatively quick and simple for trained
research assistants to administer among a large cohort of
participants in a busy clinic setting.
The Umeed study design had several other methodo-
logical strengths. Unlike other studies that have investi-
gated mental health and HIV/AIDS in a low income
setting, the Umeed study was carried out among a large
sample that included both seropositive and seronegative
individuals recruited prior to diagnosis. Thus we were
able to test hypotheses that CMD symptoms, cognitive
functioning would be associated with seropositivity inde-
pendently of the effects of diagnosis. Blind recruitment
of seropositive and seronegative participants from the
same clinic helped to ensure comparability of the two
groups and reduced risk of selection bias. There was evi-
dence from previous research to support the validity
of measures of CMD and cognitive functioning among
Goan populations.
However, there were also limitations. Due to ethical
considerations, those who were potentially most unwell:
(ie. unable to participate in 30 minute interview without
experiencing undue distress or discomfort or lacking
capacity to understand aims, participation demands and
give informed, voluntary consent) were excluded from
our sample (n = 102). Therefore, estimates for CMD
symptoms, low cognitive functioning and seropositiv-
ity are likely to be lower than the true prevalence among
people coming for testing for HIV/AIDS in Goa Medical
College. Subsequently, this may have contributed to smal-
ler effect sizes for associations between mental health ex-
posures and HIV status.
It is possible that social desirability bias may have had
an impact upon our measures of risk-taking behaviours.
Reported risk-taking behaviours were fairly low relative
to prevalence of HIV: 0.1% reported injecting drugs,
0.8% of men reported having had sex with other men,
1.9% reported having received money or gifts in ex-
change for sex; 5% reported having sex with a sex wor-
ker and 12.6% reported having sex with someone other
than a regular partner in the last year. This may have
limited our ability to control for the confounding effects
of risk-taking behaviours upon observed associations be-
tween common mental disorder/low cognitive function-
ing and HIV status.
There were other limitations to our approach to cogni-
tive testing. The cognitive screening instruments used
in Umeed were chosen because they measured the do-
mains most likely to have an impact upon access to care.
The education-adjusted norms for cognitive functioning
have not been validated among the younger Goan popu-
lation or in the context of HIV/AIDS. We were unable
to discriminate between sub-cortical deficits commonly
caused by HIV and cognitive deficits with other causes
(educational deprivation, mental sub-normality, language
issues etc.), Unmeasured confounding is a possibility.
Reverse causality cannot be ruled out. Low cognitive test
scores may have been caused by a factor other than HIV
that was associated with HIV-risk and acquisition. There
is evidence to support a link between heavy alcohol use
and poor cognitive functioning [53], as well as an associ-
ation between alcohol-related impairment and reduced
perception of sexual-risk [54]. However, given that we
found little evidence of any association between alcohol
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use and HIV status, it seems unlikely that this pathway
explains the observed relationship between low cognitive
functioning and testing positive for HIV/AIDS.
Lack of detection of an association between delayed
recall and seropositivity may be due to error in the meas-
urement of delayed recall in Umeed. Although every effort
was made to carry out interviews in an environment con-
ducive to cognitive testing, it is possible that noise and in-
terruptions to interviews had an impact, particularly on
measurement of delayed recall, the more complex of the
two cognitive tests. Measurement error may have led to
some random misclassification of delayed recall test re-
sults, which may have contributed to masking a true as-
sociation between delayed recall test results and testing
positive.
Conclusion
Umeed study findings provide tentative evidence that
prior to knowledge of HIV status, low cognitive test
scores (and perhaps CMD), may be associated with sero-
positivity among people coming for HIV-testing. Our
findings suggest that a biological mechanism may con-
tribute to the high prevalence of CMD and poor cogni-
tive functioning commonly found among people living
with HIV/AIDS. Impaired cognitive functioning and
depression-like symptoms may be the result of the same
underlying neurological damage caused by the presence
of HIV in the brain. CMD and cognitive impairment
may overlap to a greater extent than previously assumed.
In order to clarify the relationship between CMD, cogni-
tive impairment and HIV/AIDS, further research among
pre-diagnosis samples is necessary. It would be helpful
to include detailed assessments of key cognitive domains.
If a closer interrelationship between cognitive functioning
and CMD among people living with HIV/AIDS is demon-
strated, this may have implications for the way in which
we measure and treat CMD and cognitive functioning
among people living with HIV/AIDS. It will be important
to explore the possibility of early behavioural markers
(such as apathy) as predictors of later cognitive decline.
Depending on the outcome of future research, routine
integration of screening for both CMD and cognitive
deficits within Voluntary Counselling and Testing should
be considered.
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